#Sweden #Sectra #Linköping #Oxipit #ChestLink

Sectra's Acquisition of Oxipit: Revolutionizing Medical Imaging with Autonomous AI

On March 5, 2026, Sectra, a prominent international player in medical imaging IT and cybersecurity, announced an important step in the field of diagnostic imaging through the acquisition of Lithuana-based Oxipit. The acquisition grooms a new chapter in how autonomous AI will augment radiology services, particularly with Oxipit's advanced solutions tailored for efficient chest X-ray analysis.

A Groundbreaking Partnership

Oxipit is well-recognized for its pioneering efforts in AI solutions for radiology, holding the notable distinction of being the first company to secure CE Class IIB certification for autonomous AI systems focused on chest X-ray evaluations. This distinction underscores the reliability and effectiveness of Oxipit's technology, paving the way for widespread acceptance in clinical environments. The takeover comes with customary closing processes expected to finalize later in March 2026.

Historically, AI tools used in radiology have primarily functioned as decision support systems. They assist radiologists by highlighting findings and aiding in the prioritization of cases without taking over any part of the reporting process. However, by leveraging independent functionality, autonomous AI represents a significant advancement. It is designed to carry out specific diagnostic tasks under controlled conditions, complete with stringent regulatory approvals and performance benchmarks.

Autonomous AI in Action

One of Oxipit's flagship innovations, ChestLink, exemplifies this autonomous approach to radiology. Within its designated clinical parameters, this application automatically identifies and filters out high-confidence normal chest X-ray readings from a radiologist's worklist. This feature allows professionals in the field to concentrate on more complex cases, alleviating the mounting pressure caused by the escalated workload as imaging demands surge. As healthcare institutions continue to face workforce challenges, this solution becomes vital.

The autonomy of ChestLink has been validated against rigorous safety benchmarks, ensuring both efficacy and safety in medical diagnostics. The high-level regulatory compliance attained by ChestLink, with its CE Class IIb certification, reflects the elevated development and validation standards that autonomous AI applications must adhere to, particularly in the healthcare sector.

Integration with Sectra's Ecosystem

Following this acquisition, ChestLink has already been integrated into Sectra’s Amplifier Marketplace for AI, facilitating seamless adoption into established radiology workflows. This integration emphasizes Sectra's commitment to enhancing the capabilities of healthcare providers by incorporating innovative technologies that enhance operational efficiency.

Torbjörn Kronander, the President and CEO of Sectra, emphasizes the significance of this transformation: “The ability to autonomously clear high-confidence normal cases marks a transformative step for radiology. By combining clinical confidence with intelligent automation, we can expand capacity, reduce radiologist workload, and generate substantial financial benefits through higher productivity and lower costs.”

Looking Ahead

Founded in 2017, Oxipit boasts a portfolio of CE-marked AI solutions applicable not just in chest X-rays but also across CT and musculoskeletal imaging. Its solutions have already been widely adopted in international markets, demonstrating the broad applicability of their innovative technology.

Post-acquisition, the Oxipit team will operate as a dedicated AI development center within Sectra’s Imaging IT Solutions. It is worth noting that Sectra’s Amplifier service will continue to maintain an open, vendor-neutral ecosystem, enabling healthcare providers to access various AI applications derived from multiple trustworthy partners.

The financial aspect of the acquisition includes an upfront cash component coupled with additional contingent payments tied to commercial and regulatory milestones, although complete financial terms were not disclosed. Importantly, Sectra anticipates that the acquisition will not have a significant impact on the group's sales or operating profit for the current year.

As medical imaging continues to evolve in complexity and demand, the acquisition of Oxipit marks a pivotal move for Sectra, placing them at the forefront of AI innovation in healthcare. For medical professionals and institutions alike, this development promises to enhance efficiency and improve patient outcomes, pivotal in the evolving landscape of healthcare technology.

For a hands-on experience of the transformative capabilities of autonomous AI, attendees are invited to visit Booth #D02 at ECR 2026, where Sectra will showcase the ChestLink solution and demonstrate how it optimizes radiology workflows while observing high safety standards.